Glucagon-like peptide-1 receptor agonist：Semaglutide
2023-SR-611
Approved small_molecule active
Quick answer
Glucagon-like peptide-1 receptor agonist：Semaglutide for Type 2 Diabetes is a Approved program (small_molecule) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- First Tracks Biotherapeutics
- Indication
- Type 2 Diabetes
- Phase
- Approved
- Modality
- small_molecule
- Status
- active